Activation of estrogen receptors with E2 downregulates peroxisome proliferator-activated receptor γ in hepatocellular carcinoma

Oncology Reports

Volumn 30, Issue 6, 2013, Pages 3027-3031

  Lin, Yueh Min ^a,b   Velmurugan, Bharath Kumar ^c   Yeh, Yu Lan ^a,b   Tu, Chuan Chou ^d,e   Ho, Tsung Jung ^c   Lai, Tung Yuan ^f,g   Tsai, Chih Hao ^c   Tsai, Fuu Jen ^c   Tsai, Chang Hai ^h   Huang, Chih Yang ^c,h  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b JEN TEH JUNIOR COLLEGE OF MEDICINE   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d Chung Shan University   (Taiwan)

^e TAICHUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^g TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^h ASIA UNIVERSITY   (Taiwan)

Author keywords

Estrogen receptor ; Estrogen receptor ; Hepatocellular carcinoma; Nuclear receptors; Peroxisome proliferator activated receptor

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ARTICLE; CANCER PATIENT; CANCER TISSUE; CARCINOMA CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ADULT; CARCINOMA, HEPATOCELLULAR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; PPAR GAMMA; RNA, MESSENGER;

EID: 84892399196     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2793     Document Type: Article

References (29)

1. Greten TF, Papendorf F, Bleck JS, et al: Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer 92: 1862-1868, 2005.
2. El-Serag HB: Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127: S27-S34, 2004.
3. Weng CJ, Chau CF, Hsieh YS, Yang SF and Yen GC: Lucidenic acid inhibits PMA-induced invasion of human hepatoma cells through inactivating MAPK/ERK signal transduction pathway and reducing binding activities of NF-κB and AP-1. Carcinogenesis 29: 147-156, 2008.
4. El-Serag HB, Mason AC and Key C: Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 33: 62-65, 2001.
5. Vacca M, Degirolamo C, Massafra V, et al: Nuclear receptors in regenerating liver and hepatocellular carcinoma. Mol Cell Endocrinol 368: 108-119, 2012.
6. Koeffler HP: Peroxisome proliferator-activated receptor γ and cancers. Clin Cancer Res 9: 1-9, 2003.
7. Vanden Heuvel JP: Peroxisome proliferator-activated receptors (PPARS) and carcinogenesis. Toxicol Sci 47: 1-8, 1999.
8. Panigrahy D, Singer S, Shen LQ, et al: PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 110: 923-932, 2002.
9. Toyoda M, Takagi H, Horiguchi N, et al: A ligand for peroxisome proliferator activated receptor γ inhibits cell growth and induces apoptosis in human liver cancer cells. Gut 50: 563-567, 2002.
10. Wang X and Kilgore MW: Signal cross-talk between estrogen receptor alpha and beta and the peroxisome proliferator-activated receptor gamma1 in MDA-MB-231 and MCF-7 breast cancer cells. Mol Cell Endocrinol 194: 123-133, 2002.
11. Foryst-Ludwig A, Clemenz M, Hohmann S, et al: Metabolic actions of estrogen receptor beta (ERβ) are mediated by a negative cross-talk with PPARγ. PLoS Genet 4: e1000108, 2008.
12. Wu X, Subramaniam M, Grygo SB, et al: Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen. Breast Cancer Res 13: R27, 2011.
13. Ng IO, Ng M and Fan ST: Better survival in women with resected hepatocellular carcinoma is not related to tumor proliferation or expression of hormone receptors. Am J Gastroenterol 92: 1355-1358, 1997.
14. Jonas S, Bechstein WO, Heinze T, et al: Female sex hormone receptor status in advanced hepatocellular carcinoma and outcome after surgical resection. Surgery 121: 456-461, 1997.
15. Kennelly R, Kavanagh DO, Hogan AM and Winter DC: Oestrogen and the colon: potential mechanisms for cancer prevention. Lancet Oncol 9: 385-391, 2008.
16. Yu J, Shen B, Chu ES, et al: Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro. Hepatology 51: 2008-2019, 2010.
17. Borbath I and Horsmans Y: The role of PPARγ in hepatocellular carcinoma. PPAR Res 2008: 209520, 2008.
18. Li MY, Deng H, Zhao JM, Dai D and Tan XY: Peroxisome proliferator- activated receptor gamma ligands inhibit cell growth and induce apoptosis in human liver cancer BEL-7402 cells. World J Gastroenterol 9: 1683-1688, 2003.
19. Lovat PE, Oliverio S, Ranalli M, et al: GADD153 and 12-lipoxygenase mediate fenretinide-induced apoptosis of neuroblastoma. Cancer Res 62: 5158-5167, 2002.
20. Galbiati E, Caruso PL, Amari G, et al: Pharmacological actions of a novel, potent, tissue-selective benzopyran estrogen. J Pharmacol Exp Ther 303: 196-203, 2002.
21. Chen GG, Lee JF, Wang SH, Chan UP, Ip PC and Lau WY: Apoptosis induced by activation of peroxisome-proliferator activated receptor-gamma is associated with Bcl-2 and NF-kappaB in human colon cancer. Life Sci 70: 2631-2646, 2002.
22. Terashita Y, Sasaki H, Haruki N, et al: Decreased peroxisome proliferator-activated receptor gamma gene expression is correlated with poor prognosis in patients with esophageal cancer. Jpn J Clin Oncol 32: 238-243, 2002.
23. Cui Y, Miyoshi K, Claudio E, et al: Loss of the peroxisome proliferation-activated receptor gamma (PPARγ) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J Biol Chem 277: 17830-17835, 2002.
24. Yu J, Qiao L, Zimmermann L, et al: Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology 43: 134-143, 2006.
25. Li MY, Hsin MK, Yip J, Mok TS, Underwood MJ and Chen GG: PPARgamma activation extinguishes smoking carcinogen by inhibiting NNK-mediated proliferation. Am J Respir Cell Mol Biol 42: 113-122, 2010.
26. 12,14-prostaglandin J2 in human breast cancer and metastasis. Int J Cancer 103: 84-90, 2003.
27. Sakamoto A, Yokoyama Y, Umemoto M, et al: Clinical implication of expression of cyclooxygenase-2 and peroxisome proliferator activated-receptor gamma in epithelial ovarian tumours. Br J Cancer 91: 633-638, 2004.
28. Upla P, Marjomaki V, Kankaanpaa P, et al: Clustering induces a lateral redistribution of α2β1 integrin from membrane rafts to caveolae and subsequent protein kinase C-dependent internalization. Mol Biol Cell 15: 625-636, 2004.
29. Bonofiglio D, Gabriele S, Aquila S, et al: Estrogen receptor α binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor γ signaling in breast cancer cells. Clin Cancer Res 11: 6139-6147, 2005.